Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C I Edvard Smith

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
Chemical Communications (Cambridge, England)|October 20, 2015
Sequence-selective DNA recognition and enhanced cellular up-take by peptide-steroid conjugatesYara Ruiz García, Abhishek Iyer, Dorien Van Lysebetten, et al.
Immunological Reviews|March 18, 2009
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainAbdalla J Mohamed, Liang Yu, Carl-Magnus Bäckesjö, et al.
Nucleic Acid Therapeutics|February 11, 2014
Design and application of bispecific splice-switching oligonucleotidesBurcu Bestas, Graham McClorey, Ulf Tedebark, et al.
The EMBO Journal|September 13, 2003
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scatteringJosé A Márquez, C I Edvard Smith, Maxim V Petoukhov, et al.
Leukemia|February 2, 2021
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinibH Yesid Estupiñán, Qing Wang, Anna Berglöf, et al.
Immunological Reviews|January 22, 2005
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profilingJessica M Lindvall, K Emelie M Blomberg, Jouni Väliaho, et al.
Molecular Therapy. Nucleic Acids|January 25, 2013
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapyThomas C Roberts, K Emelie M Blomberg, Graham McClorey, et al.
Nucleic Acid Therapeutics|September 14, 2021
Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model SystemTea Umek, Thomas Olsson, Olof Gissberg, et al.
Nucleic Acid Therapeutics|March 3, 2022
2'-<i>O</i>-(<i>N</i>-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained ActivityDmytro Honcharenko, Cristina S J Rocha, Karin E Lundin, et al.
Journal of Human Immunity|May 22, 2026
Novel molecular assays for monitoring T cell function after HSCT in two siblings with variants in <i>DCLRE1C</i>Anna Lyytikäinen, Yasaman Shamshirgaran, Hedvig Hjerpe, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Chemical Communications (Cambridge, England)|October 20, 2015
Sequence-selective DNA recognition and enhanced cellular up-take by peptide-steroid conjugatesYara Ruiz García, Abhishek Iyer, Dorien Van Lysebetten, et al.
Immunological Reviews|March 18, 2009
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainAbdalla J Mohamed, Liang Yu, Carl-Magnus Bäckesjö, et al.
Nucleic Acid Therapeutics|February 11, 2014
Design and application of bispecific splice-switching oligonucleotidesBurcu Bestas, Graham McClorey, Ulf Tedebark, et al.
The EMBO Journal|September 13, 2003
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scatteringJosé A Márquez, C I Edvard Smith, Maxim V Petoukhov, et al.
Leukemia|February 2, 2021
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinibH Yesid Estupiñán, Qing Wang, Anna Berglöf, et al.
Immunological Reviews|January 22, 2005
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profilingJessica M Lindvall, K Emelie M Blomberg, Jouni Väliaho, et al.
Molecular Therapy. Nucleic Acids|January 25, 2013
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapyThomas C Roberts, K Emelie M Blomberg, Graham McClorey, et al.
Nucleic Acid Therapeutics|September 14, 2021
Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model SystemTea Umek, Thomas Olsson, Olof Gissberg, et al.
Nucleic Acid Therapeutics|March 3, 2022
2'-<i>O</i>-(<i>N</i>-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained ActivityDmytro Honcharenko, Cristina S J Rocha, Karin E Lundin, et al.
Journal of Human Immunity|May 22, 2026
Novel molecular assays for monitoring T cell function after HSCT in two siblings with variants in <i>DCLRE1C</i>Anna Lyytikäinen, Yasaman Shamshirgaran, Hedvig Hjerpe, et al.
Pageof 19